Overall, current experimental data on irisin suggests its potential for therapeutic purposes, especially in T2D and obesity, as irisin shares some metabolic effects with incretin hormones (141). This evidence concerns the gene FNDC5 and obesity due to melanocortin 4 receptor deficiency.